Literature DB >> 10496178

Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide.

M Delgado1, J Leceta, C Abad, C Martinez, D Ganea, R P Gomariz.   

Abstract

Macrophage activation and deactivation play essential roles in the initiation and maintenance of a successful immune response. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP), two structurally related neuropeptides, act as macrophage deactivating factors. We reported previously that VIP and PACAP inhibit IL-6, IL-12, TNF alpha and NO production, and enhance IL-10 production, from lipopolysaccharide (LPS)-stimulated macrophages. In this study, we demonstrate that VIP and PACAP down-regulate the expression of CD14, the membrane-bound LPS receptor, by inducing its rapid shedding. The soluble CD14 released by VIP and PACAP corresponds in size to the soluble CD14 released by PMA. Neither VIP/PACAP nor PMA, affect the steady-state levels of CD14 mRNA. The CD14 shedding induced by VIP/PACAP is mediated through the PAC1 specific receptors and the major transduction pathway involves the protein kinase C (PKC). The VIP/PACAP inhibition of TNF alpha and NO occurs through both CD14-dependent and -independent mechanisms, whereas the inhibition of IL-6 production appears to be strictly CD14-dependent. The shedding of CD14 by VIP and PACAP represents an important mechanism by which these neuropeptides limit the macrophage inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10496178     DOI: 10.1016/s0165-5728(99)00105-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

1.  Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis.

Authors:  R Newman; N Cuan; T Hampartzoumian; S J Connor; A R Lloyd; M C Grimm
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

2.  Gene expression analysis of neuropeptides in oral mucosa during periodontal disease in non-human primates.

Authors:  John Ferrin; Sreenatha Kirakodu; David Jensen; Ahmad Al-Attar; Rebecca Peyyala; M John Novak; Dolph Dawson; Mohanad Al-Sabbagh; Arnold J Stromberg; Luis Orraca; Janis Gonzalez-Martinez; Armando Burgos; Jeffrey L Ebersole; Octavio A Gonzalez
Journal:  J Periodontol       Date:  2018-07-20       Impact factor: 6.993

3.  Pituitary adenylate cyclase activating polypeptide: an important vascular regulator in human skin in vivo.

Authors:  Stephan Seeliger; Jörg Buddenkotte; Anjona Schmidt-Choudhury; Carine Rosignoli; Victoria Shpacovitch; Ulrike von Arnim; Dieter Metze; Roman Rukwied; Martin Schmelz; Ralf Paus; Johannes J Voegel; Wolfgang E Schmidt; Martin Steinhoff
Journal:  Am J Pathol       Date:  2010-10-01       Impact factor: 4.307

Review 4.  Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders.

Authors:  David Pozo; Elena Gonzalez-Rey; Alejo Chorny; Per Anderson; Nieves Varela; Mario Delgado
Journal:  Peptides       Date:  2007-04-20       Impact factor: 3.750

Review 5.  Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.

Authors:  Elena Gonzalez-Rey; Per Anderson; Mario Delgado
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

6.  Vasoactive intestinal polypeptide enhances oral tolerance by regulating both cellular and humoral immune responses.

Authors:  Y Wang; Y Mei; S Bao; L Xu
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

Review 7.  Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders.

Authors:  Per Anderson; Mario Delgado
Journal:  J Cell Mol Med       Date:  2008-06-28       Impact factor: 5.310

Review 8.  TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling.

Authors:  Anna Ciesielska; Marta Matyjek; Katarzyna Kwiatkowska
Journal:  Cell Mol Life Sci       Date:  2020-10-15       Impact factor: 9.261

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.